{
    "2021-06-29": [
        [
            {
                "time": "",
                "orginal_text": "294家医药公司分红582亿！恒瑞攒钱研发，迈瑞慷慨，云南白药分近50亿，Biotech几乎不分！",
                "features": {
                    "keywords": [
                        "医药公司",
                        "分红",
                        "恒瑞",
                        "研发",
                        "迈瑞",
                        "云南白药",
                        "Biotech"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "渝股点金 | 华龙证券罗涛：可关注智飞生物的交易性机会！",
                "features": {
                    "keywords": [
                        "渝股",
                        "华龙证券",
                        "罗涛",
                        "智飞生物",
                        "交易性机会"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "医药生物行业2021年中期投资策略报告：拥抱新兴产业方向 把握价值低估标的",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "新兴产业",
                        "价值低估"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "基金经理“半年考”临近，业绩冰火两重天",
                "features": {
                    "keywords": [
                        "基金经理",
                        "半年考",
                        "业绩",
                        "冰火两重天"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}